Ascendis Pharma Announces Commencement of Trading of its Ordinary Shares on Nasdaq
Rhea-AI Summary
Ascendis Pharma (Nasdaq: ASND) commenced trading of its ordinary shares on the Nasdaq Global Select Market on April 20, 2026, replacing its American Depositary Shares (ADSs).
The ordinary shares trade under the same ticker ASND, CUSIP K08588103 and ISIN DK0060606333. The company completed a mandatory exchange of all outstanding ADSs for ordinary shares, with the last ADS trading day on Nasdaq on April 17, 2026. A FAQ is available on the company investor website for details on the exchange and listing.
Positive
- Commenced trading on Nasdaq Global Select Market on April 20, 2026
- Completed 100% ADS exchange for ordinary shares as of April 20, 2026
- Ordinary shares retain ticker ASND and list under CUSIP/ISIN identifiers
Negative
- None.
News Market Reaction – ASND
In the Apr 20 session, ASND gained 0.37%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 08 | Listing transition plan | Positive | +5.8% | Announced move from ADSs to direct Nasdaq listing of ordinary shares. |
| Apr 08 | Phase 2 COACH data | Positive | +5.8% | New Week 52 COACH trial data showing added benefits in achondroplasia. |
| Apr 06 | YUVIWEL exclusivity & launch | Positive | -2.7% | FDA orphan drug exclusivity and U.S. commercial launch of YUVIWEL. |
| Mar 17 | Turner syndrome trial data | Positive | -1.3% | New InsiGHTS Phase 2 data showing comparable efficacy to daily somatropin. |
| Mar 16 | ApproaCH 2-year data | Positive | +2.0% | Two-year ApproaCH data showing durable growth and proportionality benefits. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent positive clinical and listing news often saw positive reactions, but some strong regulatory wins drew muted or negative moves, indicating occasionally inconsistent responses to good news.
Over the last few months, Ascendis reported multiple clinical and regulatory milestones and a listing transition. Data from COACH and ApproaCH trials and the New InsiGHTS study highlighted efficacy and safety across growth-disorder programs, while YUVIWEL gained U.S. FDA approval and orphan exclusivity through Feb 27, 2033. On Apr 8, 2026, Ascendis announced its plan to list ordinary shares directly on Nasdaq, which drew a +5.77% reaction. Today’s announcement confirms completion of that ADS-to-ordinary-share exchange.
Key Terms
ads financial
nasdaq global select market financial
cusip financial
isin financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
COPENHAGEN, Denmark, April 20, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced the commencement of trading of its ordinary shares on The Nasdaq Global Select Market (Nasdaq), replacing the listing of American Depositary Shares (ADSs).
The ordinary shares trade under the same ticker symbol “ASND” as previously used for the ADS listing. The ordinary shares trade under CUSIP number K08588103 and ISIN DK0060606333.
On April 8, 2026, the Company announced plans to mandatorily exchange all outstanding ADSs for ordinary shares, with each ADS exchangeable for one ordinary share listed on the Nasdaq. The last trading day for ADSs on Nasdaq was April 17, 2026. As of April 20, 2026, the Company has exchanged all outstanding ADSs for ordinary shares.
A list of frequently asked questions related to the listing of ordinary shares and exchange of ADSs is available on the Investors & News section of the Ascendis Pharma website at https://investors.ascendispharma.com.
About Ascendis Pharma A/S
Ascendis Pharma is a global biopharmaceutical company focused on applying our innovative TransCon technology platform to make a meaningful difference for patients. Guided by our core values of Patients, Science, and Passion, and following our algorithm for product innovation, we apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States. Please visit ascendispharma.com to learn more.
Forward-Looking Statements
This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis’ future operations, plans and objectives of management are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Examples of such statements include, but are not limited to, statements relating to (i) Ascendis’ ability to apply its TransCon technology platform to make a meaningful difference for patients, and (ii) Ascendis’ ability to apply TransCon to develop new therapies that demonstrate best-in-class potential to address unmet medical needs. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including, without limitation: dependence on third‑party manufacturers, distributors, and service providers for Ascendis’ products and product candidates; risks related to regulatory review and approval, including the possibility of delays, requests for additional data or analyses, restrictions or limitations on use, approval with labeling that is more limited than expected, or failure to obtain approval in the United States, European Union, or other jurisdictions; clinical development risks, including that results from ongoing or future trials may not confirm earlier data; unforeseen safety or efficacy findings in development programs or on‑market products; manufacturing, supply chain, quality, or logistics issues that could delay development or commercialization; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen research and development or selling, general and administrative expenses and other costs impacting Ascendis’ business generally; market acceptance, pricing, and reimbursement challenges, including payer coverage decisions and health technology assessments; competitive developments, including new or improved therapies; intellectual property protection, freedom‑to‑operate, and litigation risks; Ascendis’ ability to obtain additional funding, if needed, to support its business activities; cybersecurity, data privacy, and information technology disruptions; and the impact of international economic, political, legal, compliance, public health, and business factors, including tariffs, trade policies, currency fluctuations, and geopolitical events. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis’ business in general, see Ascendis’ Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 11, 2026, and Ascendis’ other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forward-looking statements, except as required by law.
Ascendis, Ascendis Pharma, the Ascendis Pharma logo, and TransCon are trademarks owned by the Ascendis Pharma group. © April 2026 Ascendis Pharma A/S.
| Investor Contacts: | Media Contact: |
| Chad Fugere | Melinda Baker |
| Ascendis Pharma | Ascendis Pharma |
| +1 (650) 519-7494 | +1 (650) 709-8875 |
